Tech Company Financing Transactions
Sparian Biosciences Funding Round
Sparian Biosciences, based in New York, received $15 million in funding from National Institutes of Health.
Transaction Overview
Company Name
Announced On
4/13/2026
Transaction Type
Debt
Amount
$15,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
345 Park Avenue South, 2nd Floor
New York, NY 10010
USA
New York, NY 10010
USA
Phone
Undisclosed
Website
Email Address
Overview
Sparian Biosciences is a clinical stage CNS-focused biopharmaceutical company committed to developing novel, transformational therapies. As neurologists and neuroscientists, co-founders Jeff Reich, MD, and Gavril Pasternak, MD, PhD, set out to build a central nervous system-oriented company with truly innovative compounds that offer new approaches to address areas of high unmet medical need. Our initial focus is on pain and substance use disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jeffrey Reich
Chief Financial Officer
Alberto Bianchinotti
Chief Operating Officer
Annie Pasternak
VP - Bus. Development
Vilomi Tringuk
Browse more venture capital transactions:
Prev: 4/13/2026: Vivatides Therapeutics venture capital transaction
Next: 4/13/2026: Aeluma venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC transactions on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs